TARA Stock — Protara Therapeutics Inc.: Cash, EV, Pipeline

Share price

$3.55

Market cap

$209.8M

Cash

$142.5M

Enterprise value

$67.3M

Balance sheet

Cash	$142.5M
Debt	$0.0M
Net cash	$142.5M
Enterprise value	$67.3M
Basic shares	59.1M shares
Fully diluted shares	76.6M shares
Fully diluted market cap	$272.1M
Cash per share	$2.41

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading TARA daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jan 12 - Feb 23	TARA-002	Phase 2	Lymphatic Malformation	—
Apr 12 - May 24	Choline Chloride for Injection	Phase 2/3	Choline Deficiency; Liver Injury	—
May 13 - Jun 24	TARA-002	Phase 3	Bladder (Urothelial, Transitional Cell) Cancer; Non-Muscle Invasive Bladder Carcinoma; Non-muscle Invasive Bladder Cancer With Carcinoma in Situ	—
Nov 12 - Dec 24	TARA-002	Phase 2	Non-muscle Invasive Bladder Cancer	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

TARA-002

Phase 2 · Active Modality: cell therapy

Aliases OK-432-based cell therapy

Partnerships Chugai Pharmaceutical (OK-432 originator; Protara holds worldwide rights ex-Japan/Taiwan)

Indications

Non-muscle invasive bladder cancer (Phase 2)
Lymphatic malformations (Stage not disclosed)

Status note Investigational cell therapy based on OK-432 immunopotentiator (approved in Japan/Taiwan for LMs and multiple oncologic indications). Phase 2 ADVANCED-2 open-label trial in high-grade CIS (Cohort A).

IV Choline Chloride

Stage not disclosed · Active Modality: substrate replacement

Target choline (nutrient)

Indications

Choline deficiency in patients on parenteral support (Stage not disclosed)

Status note Investigational phospholipid substrate replacement therapy for PS/PN patients. Orphan Drug Designation and Fast Track Designation; FDA alignment on registrational path (single study restoring choline levels in PS patients as basis for submission).

Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	TARA-002
Lead indication	Bladder (Urothelial, Transitional Cell) Cancer
Lead phase	Phase 3
Active trials	4

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07480356	Phase 3	Recruiting	Sponsor	Protara Therapeutics	—	Bladder (Urothelial, Transitional Cell) Cancer; Non-Muscle Invasive Bladder Carcinoma; Non-muscle Invasive Bladder Cancer With Carcinoma in Situ	—
NCT06910943	Phase 2/3	Recruiting	Sponsor	Protara Therapeutics	—	Choline Deficiency; Liver Injury	—
NCT05871970	Phase 2	Recruiting	Sponsor	Protara Therapeutics	—	Lymphatic Malformation	—
NCT05951179	Phase 2	Recruiting	Sponsor	Protara Therapeutics	—	Non-muscle Invasive Bladder Cancer	—

Sponsor-matched active trials from ClinicalTrials.gov (4 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 4 active trials for Protara Therapeutics on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
OrbiMed Advisors	2,220,000	+2,220,000	0.16%	2026-08-14
Baker Bros. Advisors	971,614	no change	0.02%	2026-08-14
ADAR1 Capital Management	940,512	no change	0.17%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

TARA — Protara Therapeutics Inc.